Literature DB >> 32361781

Skeletal muscle ClC-1 chloride channels in health and diseases.

Concetta Altamura1, Jean-Francois Desaphy1, Diana Conte2, Annamaria De Luca2, Paola Imbrici3.   

Abstract

In 1970, the study of the pathomechanisms underlying myotonia in muscle fibers isolated from myotonic goats highlighted the importance of chloride conductance for skeletal muscle function; 20 years later, the human ClC-1 chloride channel has been cloned; last year, the crystal structure of human protein has been solved. Over the years, the efforts of many researchers led to significant advances in acknowledging the role of ClC-1 in skeletal muscle physiology and the mechanisms through which ClC-1 dysfunctions lead to impaired muscle function. The wide spectrum of pathophysiological conditions associated with modification of ClC-1 activity, either as the primary cause, such as in myotonia congenita, or as a secondary adaptive mechanism in other neuromuscular diseases, supports the idea that ClC-1 is relevant to preserve not only for skeletal muscle excitability, but also for skeletal muscle adaptation to physiological or harmful events. Improving this understanding could open promising avenues toward the development of selective and safe drugs targeting ClC-1, with the aim to restore normal muscle function. This review summarizes the most relevant research on ClC-1 channel physiology, associated diseases, and pharmacology.

Entities:  

Keywords:  ClC-1 chloride channel; Exercise; Mexiletine; Myotonia congenita; Protopore and common gating

Mesh:

Substances:

Year:  2020        PMID: 32361781     DOI: 10.1007/s00424-020-02376-3

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  9 in total

1.  Inhibition of ClC-5 suppresses proliferation and induces apoptosis in cholangiocarcinoma cells through the Wnt/β-catenin signaling pathway.

Authors:  Zhe Shi; Liyuan Zhou; Yan Zhou; Xiaoyan Jia; Xiangjun Yu; Xiaohong An; Yanzhen Han
Journal:  BMB Rep       Date:  2022-06       Impact factor: 5.041

2.  Targeted Therapies for Skeletal Muscle Ion Channelopathies: Systematic Review and Steps Towards Precision Medicine.

Authors:  Jean-François Desaphy; Concetta Altamura; Savine Vicart; Bertrand Fontaine
Journal:  J Neuromuscul Dis       Date:  2021

Review 3.  Emerging Roles for Ion Channels in Ovarian Cancer: Pathomechanisms and Pharmacological Treatment.

Authors:  Concetta Altamura; Maria Raffaella Greco; Maria Rosaria Carratù; Rosa Angela Cardone; Jean-François Desaphy
Journal:  Cancers (Basel)       Date:  2021-02-07       Impact factor: 6.639

Review 4.  Statin-Induced Myopathy: Translational Studies from Preclinical to Clinical Evidence.

Authors:  Giulia Maria Camerino; Nancy Tarantino; Ileana Canfora; Michela De Bellis; Olimpia Musumeci; Sabata Pierno
Journal:  Int J Mol Sci       Date:  2021-02-19       Impact factor: 5.923

Review 5.  Advances and challenges in the treatment of myasthenia gravis.

Authors:  Christiane Schneider-Gold; Nils Erik Gilhus
Journal:  Ther Adv Neurol Disord       Date:  2021-12-21       Impact factor: 6.570

Review 6.  Therapeutic Targets in Amyotrophic Lateral Sclerosis: Focus on Ion Channels and Skeletal Muscle.

Authors:  Nancy Tarantino; Ileana Canfora; Giulia Maria Camerino; Sabata Pierno
Journal:  Cells       Date:  2022-01-25       Impact factor: 6.600

7.  Sequence CLCN1 and SCN4A genes in patients with nondystrophic myotonia in Chinese people.

Authors:  Yan-Xin Meng; Mei Yu; Chunmiao Liu; Haijuan Zhang; Yuxiu Yang; Jing Zhang
Journal:  Medicine (Baltimore)       Date:  2022-07-22       Impact factor: 1.817

8.  Case report: Sodium and chloride muscle channelopathy coexistence: A complicated phenotype and a challenging diagnosis.

Authors:  Serena Pagliarani; Giovanni Meola; Melania Filareti; Giacomo Pietro Comi; Sabrina Lucchiari
Journal:  Front Neurol       Date:  2022-08-23       Impact factor: 4.086

9.  Chaperone activity of niflumic acid on ClC-1 chloride channel mutants causing myotonia congenita.

Authors:  Concetta Altamura; Elena Conte; Carmen Campanale; Paola Laghetti; Ilaria Saltarella; Giulia Maria Camerino; Paola Imbrici; Jean-François Desaphy
Journal:  Front Pharmacol       Date:  2022-08-11       Impact factor: 5.988

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.